1-17 of 17
Eric Raymond
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients

Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houillier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartinie, Reza Elaidi, Celine Lerest, Stephane Oudard
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4471–4477.
https://doi.org/10.1158/1078-0432.CCR-13-3247
Published: 01 September 2014
View articletitled, Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Open the PDF for Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients in another window
Journal Articles

Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models

Maria Serova, Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre, Eric Raymond
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A68.
https://doi.org/10.1158/1078-0432.MECHRES-A68
Published: 04 March 2013
View articletitled, Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models
Open the PDF for Abstract A68: Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models in another window
Journal Articles

Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells

Lucile Astorgues-Xerri, Eric Raymond, Sandrine Faivre, Caroline Halimi, Annemilai Tijeras-Raballand, Maria Eugenia Riveiro, Sebastien Albert, Maria Serova, Anne Couvelard, Muriel Hourseau, Armand de Gramont
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A66.
https://doi.org/10.1158/1078-0432.MECHRES-A66
Published: 04 March 2013
View articletitled, Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells
Open the PDF for Abstract A66: Galectin-1 expression correlated with mesenchymal differentiation and resistance to chemotherapy in carcinoma cells in another window
Journal Articles

Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models

Maria Eugenia Riveiro, Armand de Gramont, Eric Raymond, Sandrine Faivre, Maria Serova, Annemilai Tijeras-Raballand, Safi Dokmak, Cindy Neuzillet, Lucile Astorgues-Xerri, Sebastien Albert, Guillemette Huet, Ivan Bieche
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B67.
https://doi.org/10.1158/1078-0432.MECHRES-B67
Published: 04 March 2013
View articletitled, Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models
Open the PDF for Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models in another window
Journal Articles

Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts

Annemilai Tijeras-Raballand, Celia Dos Santos, Maria Serova, Maria Eugenia Riveiro, Armand de Gramont, Sandrine Faivre, Eric Raymond
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B4.
https://doi.org/10.1158/1078-0432.MECHRES-B4
Published: 04 March 2013
View articletitled, Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
Open the PDF for Abstract B4: Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts in another window
Journal Articles

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

Sandrine Faivre, Magaly Zappa, Valérie Vilgrain, Eveline Boucher, Jean-Yves Douillard, Ho Y. Lim, Jun S. Kim, Seock-Ah Im, Yoon-Koo Kang, Mohamed Bouattour, Safi Dokmak, Chantal Dreyer, Marie-Paule Sablin, Camille Serrate, Ann-Lii Cheng, Silvana Lanzalone, Xun Lin, Maria J. Lechuga, Eric Raymond
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (13): 4504–4512.
https://doi.org/10.1158/1078-0432.CCR-10-1708
Published: 05 July 2011
View articletitled, Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
Open the PDF for Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib in another window
Journal Articles

Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma

Jean-Sébastien Guillamo, Sophie de Boüard, Samuel Valable, Lena Marteau, Pascal Leuraud, Yannick Marie, Marie-France Poupon, Jean-Jacques Parienti, Eric Raymond, Marc Peschanski
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3697–3704.
https://doi.org/10.1158/1078-0432.CCR-08-2042
Published: 01 June 2009
View articletitled, Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Open the PDF for Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma in another window
Includes: Supplementary data
Journal Articles

Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials

Eric Raymond, Carmen Kahatt, Marie Hélène Rigolet, William Sutherland, François Lokiec, Jérôme Alexandre, Bertrand Tombal, Michael Elman, Michael S. Lee, John R. MacDonald, Michael Cullen, Jean-Louis Misset, Esteban Cvitkovic
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7566–7574.
https://doi.org/10.1158/1078-0432.CCR-04-0869
Published: 29 November 2004
View articletitled, Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials
Open the PDF for Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials in another window
Journal Articles

Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells

Florence Koeppel, Virginie Poindessous, Vladimir Lazar, Eric Raymond, Alain Sarasin, Annette K. Larsen
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5604–5613.
https://doi.org/10.1158/1078-0432.CCR-04-0442
Published: 24 August 2004
View articletitled, Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells
Open the PDF for Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells in another window
Journal Articles

Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients

Jérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, Etienne C. Brain, François Lokiec, Carmen Kahatt, Sandrine Faivre, Alejandro Yovine, François Goldwasser, Sheri L. Smith, John R. MacDonald, Jean-Louis Misset, Esteban Cvitkovic
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3377–3385.
https://doi.org/10.1158/1078-0432.CCR-03-0349
Published: 24 May 2004
View articletitled, Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients
Open the PDF for Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients in another window
Journal Articles

Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin

Virginie Poindessous, Florence Koeppel, Eric Raymond, Martine Comisso, Stephen J. Waters, Annette K. Larsen
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2817–2825.
Published: 01 July 2003
View articletitled, Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin
Open the PDF for Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin in another window
Journal Articles

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors

Patricia M. LoRusso, Roy S. Herbst, Danny Rischin, Malcolm Ranson, Hilary Calvert, Eric Raymond, Dirk Kieback, Stan Kaye, Luca Gianni, Adrian Harris, Thomas Bjork, Anne-Marie Maddox, Mace L. Rothenberg, Eric J. Small, Eric H. Rubin, Andrea Feyereislova, Anne Heyes, Steven D. Averbuch, Judith Ochs, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2040–2048.
Published: 01 June 2003
View articletitled, Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors
Open the PDF for Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors in another window
Journal Articles

Effects of Hydroxyurea on Extrachromosomal DNA in Patients with Advanced Ovarian Carcinomas

Eric Raymond, Sandrine Faivre, Geoffrey Weiss, John McGill, Karen Davidson, Elzbieta Izbicka, John G. Kuhn, Craig Allred, Gary M. Clark, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1171–1180.
Published: 01 May 2001
View articletitled, Effects of Hydroxyurea on Extrachromosomal DNA in Patients with Advanced Ovarian Carcinomas
Open the PDF for Effects of Hydroxyurea on Extrachromosomal DNA in Patients with Advanced Ovarian Carcinomas in another window
Journal Articles

A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies

Sandrine Faivre, Eric Raymond, Valérie Boige, Michel Gatineau, Xavier Buthaut, Olivier Rixe, Alberto Bernareggi, Gabriella Camboni, Jean-Pierre Armand
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 43–50.
Published: 01 January 2001
View articletitled, A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies in another window
Journal Articles

Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans

Alexandre Santos, Sylvie Zanetta, Thierry Cresteil, Alain Deroussent, François Pein, Eric Raymond, Laurent Vernillet, Marie-Laure Risse, Valerie Boige, Alain Gouyette, Gilles Vassal
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 2012–2020.
Published: 01 May 2000
View articletitled, Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans
Open the PDF for Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans in another window
Journal Articles

Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin

Nadia Zeghari-Squalli, Eric Raymond, Esteban Cvitkovic, François Goldwasser
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (5): 1189–1196.
Published: 01 May 1999
View articletitled, Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin
Open the PDF for Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin in another window
Journal Articles

Molecular Detection of Telomerase-positive Circulating Epithelial Cells in Metastatic Breast Cancer Patients

Jean-Charles Soria, Laurent R. Gauthier, Eric Raymond, Christine Granotier, Luc Morat, Jean-Pierre Armand, François D. Boussin, Laure Sabatier
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (5): 971–975.
Published: 01 May 1999
View articletitled, Molecular Detection of Telomerase-positive Circulating Epithelial Cells in Metastatic Breast Cancer Patients
Open the PDF for Molecular Detection of Telomerase-positive Circulating Epithelial Cells in Metastatic Breast Cancer Patients in another window